Form 4: Immunovant Director Sells Shares for Tax Obligations

Immunovant Director Andrew J. Fromkin sold common stock totaling 22,249 shares to cover tax obligations from restricted stock unit vesting.

Summary

• Andrew J. Fromkin, a Director at Immunovant, Inc. (IMVT), reported the sale of common stock.
• The transactions occurred on December 1, 2025, and were executed under a Rule 10b5-1 trading plan adopted on December 6, 2024.
• A total of 19,351 shares were sold at a weighted average price of $23.14 per share, with prices ranging from $22.73 to $23.72.
• An additional 2,898 shares were sold at a weighted average price of $23.95 per share, with prices ranging from $23.73 to $24.13.
• The purpose of these sales was to satisfy applicable tax obligations arising from the vesting and deferred settlement of a prior award of restricted stock units.
• Following these transactions, Andrew J. Fromkin beneficially owns 85,852 shares of Immunovant common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine, pre-planned sale by a director to cover tax obligations related to RSU vesting, rather than a discretionary sale based on new information about the company's prospects.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and systematic approach to managing stock-based compensation and tax liabilities, rather than a discretionary sale based on new information.

Negatives

• The transactions represent a reduction in direct insider ownership by 22,249 shares, which could be perceived as a slight decrease in alignment with shareholder interests, although the reason is routine.

Risks

• No specific risks beyond the inherent market risk associated with stock transactions are mentioned in this Form 4 filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request to the Issuer, any security holder, or the SEC staff.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide information directly related to broader industry trends or competitive landscape. Such transactions are common for executives and directors managing their equity compensation.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan for stock sales to cover tax obligations is a standard practice among executives and directors in publicly traded companies across various industries, including biotechnology, to ensure compliance with insider trading regulations.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the pre-planned nature for tax purposes mitigates concerns about management's confidence in the company.
• Employees: No direct impact mentioned.

Next Steps

• The Reporting Person may be required to provide detailed information on specific share prices within the reported ranges upon request from the Issuer, security holders, or the SEC.

Key Dates

Keywords

Immunovant, IMVT, Andrew J. Fromkin, Director, Insider Trading, Form 4, Stock Sale, Rule 10b5-1, Tax Obligations, Restricted Stock Units, RSU Vesting